Becton, Dickinson and Company

NYSE:BDX Rapport sur les actions

Capitalisation boursière : US$42.4b

Becton Dickinson Dividendes et rachats

Dividende contrôle des critères 5/6

Becton Dickinson est une société versant des dividendes avec un rendement actuel de 2.81% qui est bien couvert par les bénéfices. La prochaine date de paiement est le 30th June, 2026 avec une date ex-dividende de 9th June, 2026.

Informations clés

2.8%

Rendement du dividende

1.2%

Rendement des rachats

Rendement total pour l'actionnaire4.0%
Rendement futur des dividendes2.6%
Croissance des dividendes4.7%
Prochaine date de paiement du dividende30 Jun 26
Date ex-dividende09 Jun 26
Dividende par actionn/a
Ratio de distribution68%

Mises à jour récentes sur les dividendes et les rachats

Becton Dickinson (NYSE:BDX) Will Pay A Dividend Of $1.05

Jan 31
Becton Dickinson (NYSE:BDX) Will Pay A Dividend Of $1.05

Recent updates

BDX: Cautious Reset In FY26 Expectations And Execution Risks Will Shape Outlook

Becton Dickinson's analyst price target has been reset from $183 to $157 as analysts factor in more cautious revenue growth, slightly softer profit margins, a higher discount rate, and a lower assumed future P/E multiple. Analyst Commentary Recent Street research around Becton Dickinson reflects a more cautious tone, with a series of price target resets and neutral stances shaping expectations for risk and reward.

Becton, Dickinson: Value Or Overvalued Even Now?

Apr 20

BDX: 2026 MedTech Setup And Buybacks Will Support Upside Potential

Analyst price targets for Becton Dickinson have edged lower, with the fair value estimate moving from about $196.08 to $192.31 as analysts factor in slightly higher discount rates, modestly softer revenue growth and profit margins, and a somewhat higher future P/E multiple. Analyst Commentary Recent Street research on Becton Dickinson reflects a mix of optimism and caution, with several firms adjusting price targets and ratings as they reassess execution risks and valuation assumptions.

BDX: 2026 MedTech Setup And Tuck In M&A Will Support Upside

Analysts have trimmed their average price target for Becton Dickinson by about $1, reflecting slightly lower fair value and P/E assumptions, along with modestly higher profit margin expectations. Analyst Commentary Recent Street research on Becton Dickinson has featured several price target changes and rating actions that point to a mix of optimism about execution and caution around valuation and growth assumptions.

BDX: 2026 MedTech Setup And Tuck In M&A Will Drive Upside

Narrative Update The latest analyst work on Becton Dickinson points to a mixed shift in price targets, with some firms raising their views by $12.30 to $15.00 while others trimmed estimates by $1.00 to $38.00, as analysts reassessed near term pressures, longer term MedTech prospects into 2026, and valuation assumptions including discount rate and future P/E inputs. Analyst Commentary Recent Street research on Becton Dickinson points to a split view, with some analysts lifting targets and others trimming them as they rework models for 2025 pressures and the setup into 2026.

BDX: 2026 MedTech Setup And Buybacks Will Shape Upside Potential

The analyst price target for Becton Dickinson has been adjusted to approximately $197 from about $195, as analysts factor in recently updated views on large cap MedTech setups, leading to slightly higher fair value and P/E assumptions. Analyst Commentary Recent research on Becton Dickinson reflects a mix of optimism and caution, with several firms adjusting price targets and ratings as they reassess large cap MedTech names and Becton Dickinson's role within that group.

BDX: 2026 Reset With Mixed Research And Product Pipeline Will Shape Returns

Analysts have trimmed their average price target on Becton Dickinson by about $9 to reflect more cautious assumptions on revenue growth and margins. This is partly offset by a willingness to apply a higher future P/E multiple as recent research updates reset expectations across the sector.

BDX: FY26 Guidance Reset Will Support More Constructive 2026 MedTech Setup

Narrative update The analyst price target for Becton Dickinson has been revised from about US$322 to about US$253. Analysts cite updated assumptions for growth, margins and future P/E, and they also reflect mixed recent Street research that includes both target raises and cuts following FY26 guidance and Q4 results.

Becton Dickinson (NYSE:BDX) Will Pay A Dividend Of $1.05

Jan 31
Becton Dickinson (NYSE:BDX) Will Pay A Dividend Of $1.05

BDX: FY26 Reset And Alaris China And Vaccine Headwinds Will Pressure Outlook

Analysts have modestly adjusted their price expectations for Becton Dickinson, with recent Street targets ranging from a reduction to $202 to an increase to $215. They are balancing near term headwinds in areas like Alaris, China, and vaccines against what some see as a more constructive setup heading into 2026 for large cap MedTech.

BDX: 2026 Reset And Headwinds Will Shape Fairly Balanced Return Potential

Analysts have modestly adjusted their fair value estimate for Becton Dickinson to about $205 per share, reflecting updated views on slower profit margin assumptions, a somewhat higher future P/E, and recent price target resets around $202 to $210 following Q4 results and FY26 guidance. Analyst Commentary Recent Street research has focused on how Becton Dickinson's latest Q4 results and FY26 outlook feed into valuation, execution risk, and growth expectations.

BDX: FY26 Reset And Business Separation Will Shape Balanced Risk Reward Outlook

We raise our fair value estimate for Becton Dickinson to $183 from $172 per share, reflecting analysts' view that a conservative FY26 reset, modestly higher long term profitability, and a slightly richer future earnings multiple more than offset near term revenue growth headwinds and higher risk premia embedded in the discount rate. Analyst Commentary Bearish analysts are converging around a more cautious outlook for Becton Dickinson, trimming price targets and highlighting execution risks that could cap near term upside.

BDX: 2026 Separation And Reset Outlook Will Shape Returns Amid Headwinds

Analysts have modestly lowered their price target on Becton Dickinson to about $203 per share from roughly $201 previously. This reflects slightly higher long term revenue growth assumptions, offset by a marginally lower profit margin outlook and cautious views on FY26 guidance amid Alaris, China, and vaccine related headwinds.

Becton Dickinson's (NYSE:BDX) Dividend Will Be Increased To $1.05

Nov 24
Becton Dickinson's (NYSE:BDX) Dividend Will Be Increased To $1.05

BDX: Modest Guidance and 2026 Separation Will Shape Future Performance Amid Headwinds

Becton Dickinson's analyst price target was reduced from approximately $206.58 to $201.49. Analysts attribute this change to cautious forward guidance, modest revenue expectations, and ongoing external headwinds highlighted in recent reports.

Some Investors May Be Willing To Look Past Becton Dickinson's (NYSE:BDX) Soft Earnings

Nov 16
Some Investors May Be Willing To Look Past Becton Dickinson's (NYSE:BDX) Soft Earnings

Becton Dickinson (NYSE:BDX) Has Announced That It Will Be Increasing Its Dividend To $1.05

Nov 09
Becton Dickinson (NYSE:BDX) Has Announced That It Will Be Increasing Its Dividend To $1.05

BDX Will Unlock New Growth Following Planned 2026 Business Separation

Becton Dickinson Analyst Price Target Narrative Update The analyst fair value estimate for Becton Dickinson was reduced slightly from $208 to approximately $206.58, with analysts citing a more conservative earnings outlook and limited growth expectations in the near term. Analyst Commentary Analyst perspectives on Becton Dickinson reflect a balanced view of the company’s near-term challenges and long-term opportunities.

Becton, Dickinson and Company: It's Wait And See For Me

Apr 27

Becton Dickinson Could Be Cure To Demand For Medtech Supplies, With Robust Pipeline

Mar 30

Versement prochain du dividende

Aujourd'huiMay 01 2026Date ex-dividendeJun 09 2026Date de paiement du dividendeJun 30 202621 days à partir de Ex DividendeAchetez dans le prochain 39 days pour recevoir le dividende à venir

Stabilité et croissance des paiements

Récupération des données sur les dividendes

Dividende stable: Les dividendes par action de BDX sont restés stables au cours des 10 dernières années.

Dividende croissant: Les paiements de dividendes de BDX ont augmenté au cours des 10 dernières années.


Rendement des dividendes par rapport au marché

Becton Dickinson Rendement des dividendes par rapport au marché
Comment le rendement du dividende de BDX se compare-t-il à celui du marché ?
SegmentRendement du dividende
Entreprise (BDX)2.8%
25% du marché (US)1.4%
25% du marché (US)4.2%
Moyenne du secteur (Medical Equipment)2.2%
Analyste prévisionnel (BDX) (jusqu'à 3 ans)2.6%

Dividende notable: Le dividende de BDX ( 2.81% ) est supérieur à celui des 25 % des payeurs de dividendes les plus faibles du marché US ( 1.4% ).

Dividende élevé: Le dividende de BDX ( 2.81% ) est faible par rapport aux 25 % des premiers payeurs de dividendes du marché US ( 4.22% ).


Bénéfice distribué aux actionnaires

Couverture des revenus: Grâce à son ratio de distribution raisonnable (68%), les dividendes versés par BDX sont couverts par les bénéfices.


Paiement en espèces aux actionnaires

Couverture des flux de trésorerie: Avec son ratio de distribution de trésorerie raisonnablement bas (45.5%), les paiements de dividendes de BDX sont bien couverts par les flux de trésorerie.


Découvrir des entreprises qui versent des dividendes élevés

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/05/01 07:06
Cours de l'action en fin de journée2026/05/01 00:00
Les revenus2025/12/31
Revenus annuels2025/09/30

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Becton, Dickinson and Company est couverte par 35 analystes. 12 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
David ToungArgus Research Company
Adam FeinsteinBarclays
Matthew MiksicBarclays